Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.03 | N/A | -8.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.03 | N/A | -8.08% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about future projects. They are focused on advancing their pipeline and remain committed to long-term goals.
Management highlighted ongoing efforts in research and development.
They emphasized the importance of upcoming trials for future growth.
The team remains focused on long-term strategic goals despite current challenges.
Kodiak Sciences reported a loss that was slightly worse than expected, which did not seem to deter investor confidence, as the stock rose by 1.17%. The management's focus on research and development and future trials suggests they are looking to build on their pipeline. Investors may be encouraged by the long-term strategy despite the current EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AST SPACEMOBILE INC Class A
Aug 11, 2025